Advanced Filters
noise

Digestive System Neoplasms Clinical Trials

A listing of Digestive System Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 507 clinical trials

Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer

This trial studies how well computed tomography works in diagnosing patients with pancreatic or hepatobiliary cancer. Computed tomography may help researchers predict how patients with pancreatic or hepatobiliary cancer may respond to chemotherapy.

18 years of age All Phase N/A
L Liwei Wang

IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer

This study is a multicenter, open-label, single-arm, phase Ib/II clinical study comprising two phases: dose confirmation phase and dose expansion phase. The objective of the dose confirmation phase is to determine the recommended Phase II dose (RP2D) of IN10018+ standard chemotherapy (albumin-bound paclitaxel + gemcitabine) and IN10018 + KN046 + …

18 years of age All Phase 1/2
J Jin Won Kim, MD

NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer

This is an open label, randomized phase 2 study of NaliCap (irinotecan liposome/Capecitabine) compared to NAPOLI (irinotecan liposome/5-FU/LV) in gemcitabine-pretreated advanced pancreatic cancer patients.

20 years of age All Phase 2
K Kathleen Christians, MD

PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples

This is an open-label, phase II study in patients with resectable and borderline resectable pancreatic cancer.

18 years of age All Phase 2
T Tsuruta Toshihisa

Investigator-initiated Clinical Trial of MIKE-1

To evaluate the safety and tolerability of Am80(Generic name: Tamibarotene, Development code: MIKE-1) in combination with gemcitabine (GEM) and nab-paclitaxel (nab-PTX) in patients with unresectable pancreatic cancer and to determine the recommended dose. Efficacy will also be exploratively investigated.

20 - 79 years of age All Phase 1/2
B Betsy Van Loo

Prediction of Surgical Resectability After FOLFIRINOX Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: the Role of Diffusion Weighted Magnetic Resonance Imaging, Radiomics and Liquid Biopsy (PeRFormanCe Trial)

In this prospective study new diagnostic tools are to be explored for the patients with borderline resectable and locally advanced pancreatic ductal adenocarcinoma (BR or LAPDA) who undergo neoadjuvant chemotherapy with FOLFIRINOX. The diagnostic work-up and therapy for the study population shall not differ from the gold standard during the …

18 years of age All Phase N/A
A An Ngo-Huang, DO

Tele-PancFit: A Multi-site Trial of Video-based Strengthening Exercise Prehabilitation for Patients With Resectable Pancreatic Cancer

To learn if a supervised exercise program during chemotherapy treatments can help to improve outcomes in patients who have been diagnosed with pancreatic cancer

18 years of age All Phase 3
L Li mao quan, doctor

U87 CART in Treatment of Advanced Pancreatic Cancer

This is a single center, open-label, phase 1 study to evaluate the safety and efficacy of U87 CART in treating advanced Pancreatic Cancer.

18 - 75 years of age All Phase 1
D Dominique GENRE, MD

Echo-endoscopy Biopsy Impact on the Circulating Tumor Cell Level

The aim of this work is to evaluate the impact of endoscopic procedures on the circulating tumoral cells level in order to evaluate the potential effects of an endoscopic procedure in the management of pancreatic tumors.

40 - 85 years of age All Phase N/A
R Rui Liu

Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer

This study is designed to explore the efficacy and safety of surufatinib combined with gemcitabine and nab-paclitaxel as peri-operative treatment in locally advanced or borderline resectable pancreatic cancer.

18 - 75 years of age All Phase 2

Simplify language using AI